Tekla Capital Management’s TherapeuticsMD TXMD Stock Holding History

Tekla Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,836	Closed	-$1.41M	–	198
2019 Q2	$1.41M	Buy	+10,836	New	+$1.94M	0.06%	149
2018 Q3	–	Sell	-4,688	Closed	-$1.46M	–	213
2018 Q2	$1.46M	Sell	4,688 -4,687	-50%	-$1.43M	0.06%	149
2018 Q1	$2.28M	Buy	9,375 +975	+12%	+$274K	0.09%	130
2017 Q4	$2.54M	Buy	+8,400	New	+$2.34M	0.1%	118
2017 Q1	–	Sell	-3,742	Closed	-$1.08M	–	144
2016 Q4	$1.08M	Sell	3,742 -2,398	-39%	-$743K	0.05%	127
2016 Q3	$2.09M	Buy	+6,140	New	+$2.24M	0.08%	116
2015 Q3	–	Sell	-29,630	Closed	-$11.6M	–	170
2015 Q2	$11.6M	Hold	29,630	–	–	0.42%	55
2015 Q1	$8.96M	Buy	+29,630	New	+$7.23M	0.36%	66

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's TXMD Position: Q3 2019 in Review

Tekla Capital Management sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 10,836 shares — an estimated $1.41M sold.

Tekla Capital Management first reported a position in TXMD in Q1 2015 and held it in 8 quarters. The position peaked at $11.6M in Q2 2015. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

Tekla Capital Management reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
Tekla Capital Management sold 10,836 TherapeuticsMD shares in Q3 2019, an estimated $1.41M.
Tekla Capital Management first reported a position in TherapeuticsMD in Q1 2015 and held it in 8 quarters.
Tekla Capital Management's TherapeuticsMD position peaked at $11.6M in Q2 2015.
150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.